Can a simple flu shot protect transplant patients?

NCT ID NCT01086904

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an inactivated H1N1 flu vaccine in 122 kidney transplant recipients who were at least 6 months post-transplant and on triple immunosuppression. The goal was to see if the vaccine could safely trigger an immune response. Researchers measured antibody levels and tracked side effects over several months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
inactivated non-adjuvanted pandemic H1N1 influenza vaccine
What this could lead to
If successful, this could show that a standard flu vaccine can safely protect kidney transplant patients, who are at higher risk from flu.
What could go wrong
This is a small, completed phase 2 trial, so results may not apply to all transplant patients. The vaccine may not trigger a strong enough immune response due to their immunosuppressant drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOSUPPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre hospitalier Lyon Sud, service de néphrologie transplantation

    Pierre-Bénite, Lyon, 69495, France

  • Hôpital E. Herriot , Service de néphrologie, transplantation et immunologie clinique

    Lyon, 69437, France

  • Service d'urologie, GH Pitié Salpêtrière

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.